Since its foundation in 1890, Santen Pharmaceutical Co., Ltd. has contributed to the protection and improvement of people's eyesight and health. Santen's integrated operations extend from research and development to production and sales of prescription and over-the-counter pharmaceuticals.

Today, Santen specializes in original ophthalmic and anti-rheumatic pharmaceuticals as it works to create superior pharmaceuticals for all types of ophthalmic disorders and offer information that meets clinical needs. As a result, Santen leads Japan's market for prescription ophthalmics, which represent over 80 percent of Company sales.

To enhance its new product pipeline and support efficient research and development, Santen is strengthening its own R&D organization while also forming alliances that allow the Company to take advantage of external resources. Santen has established a global network of technological alliances with pharmaceutical companies, universities, research centers and venture businesses. Through these tie-ups, Santen actively engages in information exchange, licensing and joint development, and applies the results of these activities to efficient development of new pharmaceuticals.